Effects of cilostazol on angiographic restenosis after coronary stent placement

Seong Wook Park, Cheol Whan Lee, Hyun Sook Kim, Nae Hee Lee, Deuk Young Nah, Myeongki Hong, Jae Joong Kim, Seung Jung Park

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

This study evaluates the impact of cilostazol on poststenting restenosis. Cilostazol is a potent antiplatelet agent with antiproliferative properties. Few data are available about the effect of cilostazol on poststenting restenosis. Four hundred nine patients (494 lesions) who were scheduled for elective stenting were randomized to receive aspirin plus ticlopidine (group I, n = 201, 240 lesions) or aspirin plus cilostazol (group II, n = 208, 254 lesions), starting 2 days before stenting. Ticlopidine was given for 1 month and cilostazol for 6 months. Follow-up angiography was performed at 6 months, and clinical evaluation at regular intervals. Baseline characteristics were similar between the 2 groups. The procedural success rate was 99.6% in group I and 100% in group II. There were no cases of stent thrombosis after stenting. Angiographic follow-up was performed in 380 of the 494 eligible lesions and the angiographic restenosis rate was 27% in group I and 22.9% in group II (p = NS). However, diffuse type in-stent restenosis was more common in group I than in group II (54.2% vs 26.8%, respectively, p < 0.05). In diabetic patients, the angiographic restenosis rate was 50% in group I and 21.7% in group II (p < 0.05). Clinical events during follow-up did not differ between the 2 groups. In conclusion, aspirin plus cilostazol seems to be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine, but it does not reduce the overall angiographic restenosis rate after elective coronary stenting.

Original languageEnglish
Pages (from-to)499-503
Number of pages5
JournalAmerican Journal of Cardiology
Volume86
Issue number5
DOIs
Publication statusPublished - 2000 Sep 1

Fingerprint

Coronary Restenosis
Stents
Ticlopidine
Aspirin
Platelet Aggregation Inhibitors
cilostazol
Angiography
Thrombosis

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Park, Seong Wook ; Lee, Cheol Whan ; Kim, Hyun Sook ; Lee, Nae Hee ; Nah, Deuk Young ; Hong, Myeongki ; Kim, Jae Joong ; Park, Seung Jung. / Effects of cilostazol on angiographic restenosis after coronary stent placement. In: American Journal of Cardiology. 2000 ; Vol. 86, No. 5. pp. 499-503.
@article{ef823feb5add48b89e5a6eb94fcfb5d9,
title = "Effects of cilostazol on angiographic restenosis after coronary stent placement",
abstract = "This study evaluates the impact of cilostazol on poststenting restenosis. Cilostazol is a potent antiplatelet agent with antiproliferative properties. Few data are available about the effect of cilostazol on poststenting restenosis. Four hundred nine patients (494 lesions) who were scheduled for elective stenting were randomized to receive aspirin plus ticlopidine (group I, n = 201, 240 lesions) or aspirin plus cilostazol (group II, n = 208, 254 lesions), starting 2 days before stenting. Ticlopidine was given for 1 month and cilostazol for 6 months. Follow-up angiography was performed at 6 months, and clinical evaluation at regular intervals. Baseline characteristics were similar between the 2 groups. The procedural success rate was 99.6{\%} in group I and 100{\%} in group II. There were no cases of stent thrombosis after stenting. Angiographic follow-up was performed in 380 of the 494 eligible lesions and the angiographic restenosis rate was 27{\%} in group I and 22.9{\%} in group II (p = NS). However, diffuse type in-stent restenosis was more common in group I than in group II (54.2{\%} vs 26.8{\%}, respectively, p < 0.05). In diabetic patients, the angiographic restenosis rate was 50{\%} in group I and 21.7{\%} in group II (p < 0.05). Clinical events during follow-up did not differ between the 2 groups. In conclusion, aspirin plus cilostazol seems to be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine, but it does not reduce the overall angiographic restenosis rate after elective coronary stenting.",
author = "Park, {Seong Wook} and Lee, {Cheol Whan} and Kim, {Hyun Sook} and Lee, {Nae Hee} and Nah, {Deuk Young} and Myeongki Hong and Kim, {Jae Joong} and Park, {Seung Jung}",
year = "2000",
month = "9",
day = "1",
doi = "10.1016/S0002-9149(00)01001-8",
language = "English",
volume = "86",
pages = "499--503",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

Effects of cilostazol on angiographic restenosis after coronary stent placement. / Park, Seong Wook; Lee, Cheol Whan; Kim, Hyun Sook; Lee, Nae Hee; Nah, Deuk Young; Hong, Myeongki; Kim, Jae Joong; Park, Seung Jung.

In: American Journal of Cardiology, Vol. 86, No. 5, 01.09.2000, p. 499-503.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of cilostazol on angiographic restenosis after coronary stent placement

AU - Park, Seong Wook

AU - Lee, Cheol Whan

AU - Kim, Hyun Sook

AU - Lee, Nae Hee

AU - Nah, Deuk Young

AU - Hong, Myeongki

AU - Kim, Jae Joong

AU - Park, Seung Jung

PY - 2000/9/1

Y1 - 2000/9/1

N2 - This study evaluates the impact of cilostazol on poststenting restenosis. Cilostazol is a potent antiplatelet agent with antiproliferative properties. Few data are available about the effect of cilostazol on poststenting restenosis. Four hundred nine patients (494 lesions) who were scheduled for elective stenting were randomized to receive aspirin plus ticlopidine (group I, n = 201, 240 lesions) or aspirin plus cilostazol (group II, n = 208, 254 lesions), starting 2 days before stenting. Ticlopidine was given for 1 month and cilostazol for 6 months. Follow-up angiography was performed at 6 months, and clinical evaluation at regular intervals. Baseline characteristics were similar between the 2 groups. The procedural success rate was 99.6% in group I and 100% in group II. There were no cases of stent thrombosis after stenting. Angiographic follow-up was performed in 380 of the 494 eligible lesions and the angiographic restenosis rate was 27% in group I and 22.9% in group II (p = NS). However, diffuse type in-stent restenosis was more common in group I than in group II (54.2% vs 26.8%, respectively, p < 0.05). In diabetic patients, the angiographic restenosis rate was 50% in group I and 21.7% in group II (p < 0.05). Clinical events during follow-up did not differ between the 2 groups. In conclusion, aspirin plus cilostazol seems to be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine, but it does not reduce the overall angiographic restenosis rate after elective coronary stenting.

AB - This study evaluates the impact of cilostazol on poststenting restenosis. Cilostazol is a potent antiplatelet agent with antiproliferative properties. Few data are available about the effect of cilostazol on poststenting restenosis. Four hundred nine patients (494 lesions) who were scheduled for elective stenting were randomized to receive aspirin plus ticlopidine (group I, n = 201, 240 lesions) or aspirin plus cilostazol (group II, n = 208, 254 lesions), starting 2 days before stenting. Ticlopidine was given for 1 month and cilostazol for 6 months. Follow-up angiography was performed at 6 months, and clinical evaluation at regular intervals. Baseline characteristics were similar between the 2 groups. The procedural success rate was 99.6% in group I and 100% in group II. There were no cases of stent thrombosis after stenting. Angiographic follow-up was performed in 380 of the 494 eligible lesions and the angiographic restenosis rate was 27% in group I and 22.9% in group II (p = NS). However, diffuse type in-stent restenosis was more common in group I than in group II (54.2% vs 26.8%, respectively, p < 0.05). In diabetic patients, the angiographic restenosis rate was 50% in group I and 21.7% in group II (p < 0.05). Clinical events during follow-up did not differ between the 2 groups. In conclusion, aspirin plus cilostazol seems to be an effective antithrombotic regimen with comparable results to aspirin plus ticlopidine, but it does not reduce the overall angiographic restenosis rate after elective coronary stenting.

UR - http://www.scopus.com/inward/record.url?scp=0342955606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342955606&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(00)01001-8

DO - 10.1016/S0002-9149(00)01001-8

M3 - Article

C2 - 11009265

AN - SCOPUS:0342955606

VL - 86

SP - 499

EP - 503

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -